Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
NCT05595031 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400
Last updated 2022-10-26
Summary
The purpose of this project is to evaluate the clinical impact of the use of glucocorticoids beyond 10 days for patients with critical COVID-19 at MDMC.
Conditions
- Covid 19
Sponsors & Collaborators
-
Methodist Health System
lead OTHER
Principal Investigators
-
Kristen Rahmanzadeh, PharmD · The Methodist Hospital Research Institute
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-19
- Primary Completion
- 2023-10-19
- Completion
- 2023-10-19
Countries
- United States
Study Locations
More Related Trials
-
GLS-5310 Vaccine in Healthy Volunteers for the Prevention of SARS-CoV-2 (COVID-19)
NCT05085639 ·Status: UNKNOWN ·Phase: PHASE1
-
LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
NCT05780268 ·Status: COMPLETED ·Phase: PHASE3
-
Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines
NCT04889209 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
NCT06585241 ·Status: RECRUITING ·Phase: PHASE4
-
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
NCT04659109 ·Status: COMPLETED ·Phase: PHASE2
-
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
NCT04551898 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
NCT04532294 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease
NCT05043246 ·Status: UNKNOWN
-
PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS
NCT05279365 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects
NCT05977101 ·Status: UNKNOWN ·Phase: NA
-
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
NCT05144139 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
NCT07089706 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)
NCT05631405 ·Status: RECRUITING ·Phase: NA
-
SARS Coronavirus Vaccine (SARS-CoV)
NCT00533741 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of LY3819253 (LY-CoV555) in Healthy Participants
NCT04537910 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults
NCT05389319 ·Status: RECRUITING ·Phase: PHASE1
-
To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
NCT04955626 ·Status: COMPLETED ·Phase: PHASE3
-
First-In-Human Study Of Orally Administered CoV2-OGEN1 In Healthy Subjects
NCT04893512 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806
NCT01801293 ·Status: COMPLETED ·Phase: PHASE1
-
GLS-5310 Vaccine in Healthy Volunteers as a Booster for SARS-CoV-2 (COVID-19)
NCT05182567 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19
NCT04411628 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of DXP604 in Patients With Mild to Moderate COVID-19
NCT05381519 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
NCT04505722 ·Status: COMPLETED ·Phase: PHASE3
-
NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)
NCT04442230 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine
NCT05313035 ·Status: COMPLETED ·Phase: PHASE2/PHASE3